Does the media refer more to REGN or AMGN?

In the previous week, Amgen had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 40 mentions for Amgen and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Amgen's score of 0.93 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 26 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GILD or REGN?

In the previous week, Gilead Sciences had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 34 mentions for Gilead Sciences and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Gilead Sciences' score of 0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 13 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor REGN or MRNA?

In the previous week, Moderna had 35 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Moderna and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Moderna's score of 0.31 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 18 Very Positive mention(s) 19 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 8 Very Negative mention(s) Neutral

Does the media refer more to REGN or NTLA?

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than Intellia Therapeutics. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 4 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Intellia Therapeutics' score of 0.80 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or REGN?

In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 21 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Vir Biotechnology's score of 0.17 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Regeneron Pharmaceuticals (REGN) Competitors

$797.22 +0.88 (+0.11%)

As of 11:00 AM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? Regeneron Pharmaceuticals's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Amgen had 17 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 40 mentions for Amgen and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Amgen's score of 0.93 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	26 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$15.53B	5.28	$4.50B	$40.46	19.68
Amgen	$36.75B	6.38	$7.71B	$16.09	26.98

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Amgen	22.95%	124.14%	13.18%

Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Regeneron Pharmaceuticals presently has a consensus target price of $845.21, indicating a potential upside of 6.14%. Amgen has a consensus target price of $387.93, indicating a potential downside of 10.62%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.77
Amgen	3 Sell rating(s)	16 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.30

Summary

Regeneron Pharmaceuticals beats Amgen on 10 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.1%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.63	$8.51B	-$2.67	N/A
Regeneron Pharmaceuticals	$15.53B	5.28	$4.50B	$40.46	19.68

In the previous week, Gilead Sciences had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 34 mentions for Gilead Sciences and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Gilead Sciences' score of 0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	13 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gilead Sciences presently has a consensus price target of $159.33, indicating a potential upside of 1.25%. Regeneron Pharmaceuticals has a consensus price target of $845.21, indicating a potential upside of 6.14%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.79
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 11 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals currently has a consensus target price of $845.21, suggesting a potential upside of 6.14%. Moderna has a consensus target price of $101.45, suggesting a potential downside of 57.10%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.77
Moderna	4 Sell rating(s)	15 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.12

In the previous week, Moderna had 35 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Moderna and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Moderna's score of 0.31 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	18 Very Positive mention(s)	19 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	8 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$15.53B	5.28	$4.50B	$40.46	19.68
Moderna	$1.94B	48.57	-$2.82B	-$7.99	N/A

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Regeneron Pharmaceuticals beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Regeneron Pharmaceuticals currently has a consensus price target of $845.21, suggesting a potential upside of 6.14%. Intellia Therapeutics has a consensus price target of $20.72, suggesting a potential upside of 82.69%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.77
Intellia Therapeutics	5 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.26

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$15.53B	5.28	$4.50B	$40.46	19.68
Intellia Therapeutics	$67.67M	23.48	-$412.69M	-$3.36	N/A

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Intellia Therapeutics' net margin of -672.16%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than Intellia Therapeutics. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 4 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Intellia Therapeutics' score of 0.80 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Vir Biotechnology presently has a consensus price target of $21.86, suggesting a potential upside of 108.76%. Regeneron Pharmaceuticals has a consensus price target of $845.21, suggesting a potential upside of 6.14%. Given Vir Biotechnology's higher possible upside, equities analysts clearly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.77

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Vir Biotechnology's net margin of 0.00%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	25.84	-$437.99M	-$1.86	N/A
Regeneron Pharmaceuticals	$15.53B	5.28	$4.50B	$40.46	19.68

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 21 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 1.08 beat Vir Biotechnology's score of 0.17 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 13 of the 16 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$82.00B	$3.93B	$7.43B	$12.86B
Dividend Yield	0.50%	3.66%	2.51%	19.61%
P/E Ratio	19.69	12.63	274.94	25.22
Price / Sales	5.28	1,201.64	623.57	99.68
Price / Cash	18.54	118.95	76.19	51.56
Price / Book	2.69	16.07	10.40	5.96
Net Income	$4.50B	-$22.69M	$3.50B	$380.92M
7 Day Performance	6.63%	-6.92%	-3.89%	-3.33%
1 Month Performance	2.77%	-12.35%	-7.10%	-5.34%
1 Year Performance	39.86%	2.13%	1.70%	-4.58%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	4.5093 of 5 stars	$793.42 -0.4%	$845.21 +6.5%	+38.2%	$81.73B	$15.53B	19.62	15,410	Trending News Analyst Upgrade Insider Trade
AMGN Amgen	4.1316 of 5 stars	$413.08 +2.6%	$385.79 -6.6%	+46.0%	$223.32B	$38.10B	25.67	31,500	Positive News Analyst Forecast Analyst Revision
GILD Gilead Sciences	3.1261 of 5 stars	$146.85 +1.8%	$159.15 +8.4%	+33.0%	$182.09B	$30.46B	N/A	17,000	Trending News Analyst Revision
MRNA Moderna	1.7768 of 5 stars	$196.48 +4.8%	$78.17 -60.2%	+753.2%	$78.44B	$1.94B	N/A	4,700	Trending News Analyst Forecast
NTLA Intellia Therapeutics	3.1701 of 5 stars	$11.71 -5.3%	$20.72 +76.9%	-56.3%	$1.64B	$67.67M	N/A	377	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Does the media refer more to REGN or AMGN?

Which has stronger valuation and earnings, REGN or AMGN?

Is REGN or AMGN more profitable?

Which has more volatility and risk, REGN or AMGN?

Do institutionals & insiders believe in REGN or AMGN?

Is REGN or AMGN a better dividend stock?

Do analysts prefer REGN or AMGN?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Is GILD or REGN more profitable?

Which has more risk & volatility, GILD or REGN?

Is GILD or REGN a better dividend stock?

Which has better earnings and valuation, GILD or REGN?

Does the media favor GILD or REGN?

Do institutionals and insiders hold more shares of GILD or REGN?

Do analysts prefer GILD or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Do institutionals & insiders have more ownership in REGN or MRNA?

Do analysts prefer REGN or MRNA?

Does the media favor REGN or MRNA?

Which has more volatility and risk, REGN or MRNA?

Which has preferable earnings and valuation, REGN or MRNA?

Is REGN or MRNA more profitable?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Do analysts recommend REGN or NTLA?

Which has better earnings and valuation, REGN or NTLA?

Is REGN or NTLA more profitable?

Which has more risk and volatility, REGN or NTLA?

Do insiders & institutionals hold more shares of REGN or NTLA?

Does the media refer more to REGN or NTLA?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Do analysts recommend VIR or REGN?

Is VIR or REGN more profitable?

Which has better valuation & earnings, VIR or REGN?

Do institutionals & insiders hold more shares of VIR or REGN?

Does the media prefer VIR or REGN?

Which has more volatility & risk, VIR or REGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools